Daewha Pharmaceutical

Daewha Pharmaceutical

Global First Oral Anticancer Drug

Advancing into China with "Liporaxel"

Leedeily, Shin Min-jun

Daewha Pharmaceutical's domestic sales account for over 96%,

and it hasn't yet established a clear global presence.

More than 95% of the Chinese pharmaceutical market consists of generics (copied drugs),

so a product with unique technology could potentially achieve good results in China.

The products are as follows:

Oral anticancer drug Liporaxel,

Transdermal dementia drug (patch-type dementia treatment),

Amalian hyaluronic acid filler

Liporaxel is a modified new drug of paclitaxel, a global market with a size of 5 trillion won. Paclitaxel has been used as an anticancer drug for over 30 years. Unlike paclitaxel, Liporaxel does not require a solubilizer or auxiliary equipment.

The size of the Chinese paclitaxel market is said to be approximately 1.5 trillion won.

It's certainly worth targeting.

Daewha Pharmaceutical has invested in the Chinese market for over 10 years,

and expects to see increased profits next year.